Blog
RSS FeedPosted by Michael Wonder on 02 Sep 2023
Lisocabtagene maraleucel in second-line B-cell lymphoma: additional benefit for certain patients
1 September 2023 - On the basis of the available data, there is a hint of a non-quantifiable added benefit ...
Posted by Michael Wonder on 14 Dec 2021
EU regulation passed: G-BA works on European HTA assessment
14 December 2021 - Today the EU Parliament passed the EU-HTA regulation for a joint health technology assessment, which includes, ...
Posted by Michael Wonder on 09 Aug 2021
Quality assurance requirements of the G-BA also apply to new CAR-T cell therapy
5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and ...
Posted by Michael Wonder on 22 Apr 2021
Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe
22 April 2021 - When Bluebird Bio secured European approval for its gene therapy to treat beta thalassaemia in 2019, ...
Posted by Michael Wonder on 17 Sep 2020
The best possible security of supply for cancer therapy with CAR-T cells
17 September 2020 - Medical facilities that treat patients with novel cell therapies (CAR-T cells) must meet newly defined quality requirements. ...
Posted by Michael Wonder on 14 Jan 2019
Rexgenero's lead product REX-001 selected for the EUnetHTA prioritisation list for joint assessments
7 January 2019 - The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant ...
Posted by Michael Wonder on 17 Dec 2018
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
17 December 2018 - Could reinsures solve problem of high upfront costs of developing potentially life-saving treatments? ...
Posted by Michael Wonder on 12 Sep 2018
A breakthrough cancer drug has been approved. Now comes the battle over the price.
12 Septemner 2018 - Novartis' breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its ...
Posted by Michael Wonder on 19 Sep 2016
Talimogene laherparepvec in melanoma: additional clinical benefit not proven
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment. ...